BIOLASE to Collaborate With St. Barnabas Medical Center in Study of New Laser, Code Named DRAGON(TM)

BIOLASE to Collaborate With St. Barnabas Medical Center in Study of New Laser, 
Code Named DRAGON(TM) 
The Market Leader in All-Tissue Dental Lasers Has Developed a Unique
Dual Wavelength Laser to Target at Several Medical Markets 
IRVINE, CA -- (Marketwired) -- 02/04/14 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, including the Company's proprietary WaterLase, and a pioneer
in laser surgery in other medical specialties, as well as a
distributor of digital radiography and Galaxy CAD/CAM systems for
dentistry, today announced that it has agreed to collaborate with the
St. Barnabas Medical Center in New York City to conduct specified
research with its recently developed and patent-pending,
revolutionary new surgical laser, code named the DRAGON(TM). 
Dr. Dara Rosenberg of St. Barnabas Hospital said, "I am delighted to
work with BIOLASE on developing a wound-healing protocol for their
new dual wavelength laser. Once Institutional Review Board approval
is obtained, I believe a subsequent wound healing study using this
protocol has the potential to significantly enhance our current wound
healing therapies." 
With the DRAGON laser, BIOLASE has recently successfully combined its
proprietary WaterLase technology with a diode laser to deliver
simultaneous and intertwined laser energy in the same delivery
system. The result of two years of research and development, DRAGON
differs from BIOLASE's current laser products in that the user may
power two or more different wavelengths of laser energy, with the
same hand piece, simultaneously. This creates interesting clinical
capabilities that could potentially apply to a variety of medical
applications. The Company has recently built its tenth
fully-functioning prototype, six of which are already involved in
pre-clinical testing by key opinion leaders and physicians.  
"The DRAGON elevates BIOLASE's patented WaterLase technology to new
levels," said Professor and Doctor Norbert Gutknecht of the Aachen
Center for Laser Dentistry (the "AALZ") in Germany, the world's
largest university-based laser education institute. "The effects of
combining two different laser energies emitting through a single
fiber is not only remarkable from a technological point of view, but
it will revolutionize the biophysical interaction with hard and soft
tissue. After undertaking in depth preclinical research with this new
extraordinary technology, I am very impressed by the histological
results. DRAGON technology offers a radical new hard and soft tissue
cutting efficiency combined with a strong pain reduction effects and
has the potential to set new landmarks in treating infected tissues
due to its high bactericidal effect. One of the preclinical
advantages that I have most observed is a notable decrease of the
post-op recovery period. We have generated a tremendous amount of
positive preclinical data in a very short period of time which will
be integrated in a number of new treatment clinical protocols." 
Dr. Yosef Krespi, M.D., F.A.C.S, an otolaryngologist at the New York
Head & Neck Institute, a part of the North Shore Long Island Jewish
hospital system, where he also chairs the Sleep Disorders Center,
stated, "I have had the opportunity to test the DRAGON in my
laboratory, and this new laser has superior qualities and outstanding
performance that should allow surgeons to perform a wide range of
minimally invasive hard- and soft-tissue procedures. The DRAGON, with
its two unique wavelengths, has the potential to revolutionize laser
surgery and become the standard of care in ENT. In addition to its
conventional laser tissue effects of precise ablation, coagulation,
and char-free cutting, it has the potential to offer a number of
unique characteristics such as bio-stimulation, anti-inflammatory,
microbial reduction, and biofilm disruption." 
Federico Pignatelli, Chairman and CEO, stated, "BIOLASE has
historically been categorized as a dental laser company. This
innovative new multiple-wavelength laser, code named the DRAGON, has
the potential to provide practitioners, across several additional
medical specialties, with better treatments and outcomes for their
patients. Pending required market clearance by the U.S. Food and Drug
Administration, we look forward to introducing this product into the
The DRAGON is currently targeted toward several new medical markets
for BIOLASE including: 
1. Wound healing for burns and trauma: approximately 70,000 people
suffer severe large body surface area full-thickness burns each year
in the U.S. and we believe that wound debridement is integral during
the painful healing phase to optimize clinical outcomes. 
 2. Wound
healing for chronic wounds: some 2.2 million patients in the U.S. and
12.5 million patients worldwide suffer from chronic non-healing
wounds which can include venous stasis ulcers, decubitus ulcers, and
diabetic foot ulcers. Laser therapy could excise the dead (necrotic)
tissue of these difficult-to-treat wounds, leaving the clean, healthy
tissue and a fresh wound bed. 
 3. Otolaryngology ("ENT") surgery:
this includes solutions for nasal turbinate reductions, sleep apnea
interventions, and the surgical treatment of chronic rhino sinusitis,
or CRS. There are approximately 700,000 CRS procedures treated
surgically each year in the U.S., and up to 30% of these cases need
surgical revisions because of poor healing outcomes. 
Ophthalmology: treating presbyopia requires precisely cutting the
ciliary muscles of the lens, thereby restoring visual accommodation.
Keratoconjunctivitis sicca, or "dry eye syndrome," is another target
area. BIOLASE has previously addressed this area through a variety of
filed and pending U.S. and international patents.  
President and COO Alexander K. Arrow, MD, said, "Our next step is to
inquire with the Food and Drug Administration regarding acceptable
clinical protocols to generate data to support a 510(k) application
for the use of the DRAGON as a surgical tool in multiple medical
fields. Once the clinical trial design is set, the data generated
could be used to support a CE Mark which will allow BIOLASE to
provide this technology to clinicians in Europe." 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners and
in-office milling machines; products that are focused on technologies
that advance the practice of dentistry and medicine. The Company's
proprietary laser products incorporate approximately 300 patented and
patent-pending technologies designed to provide biologically
clinically superior performance with less pain and faster recovery
times. Its innovative products provide cutting-edge technology at
competitive prices to deliver the best results for dentists and
patients. BIOLASE's principal products are revolutionary dental laser
systems that perform a broad range of dental procedures, including
cosmetic and complex surgical applications, and a full line of dental
imaging equipment. BIOLASE has sold more than 24,800 lasers. Other
laser products under development address ophthalmology and other
medical and consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at, Facebook at, Twitter at,
Pinterest at, LinkedIn at, Google+ at, Instagram at and YouTube at  
BIOLASE(R), WaterLase(R), and DRAGON(TM) are registered trademarks or
trademarks of BIOLASE, Inc. 
For further information, please contact: 
Michael Porter
Porter, LeVay & Rose, Inc. 
Press spacebar to pause and continue. Press esc to stop.